CLINICAL TRIALS PROFILE FOR BALOXAVIR MARBOXIL
✉ Email this page to a colleague
All Clinical Trials for baloxavir marboxil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02949011 ↗ | Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications | Completed | Shionogi | Phase 3 | 2017-01-11 | The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset. |
| NCT02954354 ↗ | A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza | Completed | Shionogi | Phase 3 | 2016-12-08 | The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus infection. |
| NCT03629184 ↗ | Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms | Completed | Hoffmann-La Roche | Phase 3 | 2018-11-20 | This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with influenza-like symptoms. |
| NCT03653364 ↗ | Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms | Recruiting | Hoffmann-La Roche | Phase 3 | 2019-01-23 | This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to <1 year with influenza like symptoms |
| NCT03684044 ↗ | Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza | Completed | Hoffmann-La Roche | Phase 3 | 2019-01-08 | This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in hospitalized patients with influenza. |
| NCT03959332 ↗ | Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants | Completed | Shionogi | N/A | 2019-06-19 | This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants. |
| NCT03959332 ↗ | Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants | Completed | Hoffmann-La Roche | N/A | 2019-06-19 | This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for baloxavir marboxil
Condition Name
Clinical Trial Locations for baloxavir marboxil
Trials by Country
Clinical Trial Progress for baloxavir marboxil
Clinical Trial Phase
Clinical Trial Sponsors for baloxavir marboxil
Sponsor Name
